---
schema_version: "secwatch.filing_event.v1"
accession: "0000939767-24-000074"
form_type: "8-K"
ticker: "EXEL"
cik: "0000939767"
company_name: "EXELIXIS, INC."
filed_at: "2024-05-20T23:59:59+00:00"
generated_at: "2026-06-01T14:09:16.263532+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Exelixis settles CABOMETYX patent litigation; Cipla generic launch from Jan 1, 2031

## Summary
- Settlement with Cipla resolves two Hatch-Waxman patent suits over CABOMETYX (cabozantinib).
- Cipla receives license to market generic CABOMETYX in US starting January 1, 2031, if FDA approved.
- All ongoing Delaware district court litigation will be dismissed pending FTC review.
- Agreement confidential and subject to review by FTC and DOJ.

## SEC filing metadata
- accession: 0000939767-24-000074
- form_type: 8-K
- ticker: EXEL
- cik: 0000939767
- company_name: EXELIXIS, INC.
- filed_at: 2024-05-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/939767/000093976724000074/0000939767-24-000074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/939767/000093976724000074/exel-20240520.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000939767-24-000074
- JSON: https://secwatch.observer/filing/0000939767-24-000074.json
- Plain text: https://secwatch.observer/filing/0000939767-24-000074.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.